Synthesis and Binding Profile Using Molecular Dynamics of New Building Blocks for PSMA Theranostics and the PSMA617-Cystine-Doxorubicin Therapeutic Bioconjugate Against Prostate Cancer

07 April 2023, Version 2
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

GCPII also known as Prostate Specific Membrane Antigen (PSMA), is overexpressed in prostate cancer (PCa) cells and provide a biomarker for tumor targeting PSMA receptor. The development of lysine-urea-glutamate pharmacophore based inhibitors targeting PSMA for theranostics applications led to PSMA11 and PSMA617. In PSMA11, this pharmacophore is attached via aminohexanoic acid (Ahx) spacer to a chelator while in PSMA617 the pharmacophore is connecting with the linker 2-naphthyl-L-Ala, trans-4-(aminomethyl)cyclohexanecarboxylic acid and then to chelator. Here, we synthesized: (a) a squaramide analog of lysine-urea-glutamic acid; (b) two new building blocks for PSMA theranostics in which lysine-urea-glutamic acid was attached with two (i) phenyl alanine residues to target arene binding site of PSMA receptor and (ii) amino hexanoic acid residues. (d) Inspired from the promising structure of PSMA617 we synthesized a new bioconjugate prodrug in which we replaced the chelator in PSMA617 with a cleavable cystine linker attached to the anticancer drug Doxorubicin. Induced fit docking and MD simulations explored the binding profile of the new molecules.

Keywords

arene binding site
bioconjugate
cleavable linker
cystine
docking calculations
doxorubicin
induced fit
molecular dynamics
Prostate Specific Membrane Antigen
PSMA11
PSMA617
squaramide
theranostics

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.